Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial
- 19 February 2014
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 63 (15), 1493-1499
- https://doi.org/10.1016/j.jacc.2014.01.038
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- AstraZeneca, Merck & Co., Inc., GlaxoSmithKline, Roche, and Bristol-Myers Squibb
- AstraZeneca, Eli Lilly and Company, Bristol-Myers Squibb, Terumo Inc., Medtronic, and Vascular Solutions
- GlaxoSmithKline, Pfizer Inc., and Sanofi-Aventis
- NYU School of Medicine, Sanofi-Aventis, and Servier
- Accumetrics, AstraZeneca, CSL Behring, Essentialis, GlaxoSmithKline, Merck & Co., Inc., Regeneron, Sanofi-Aventis, and Takeda
- AstraZeneca
- AstraZeneca, Eli Lilly and Company/Daiichi Sankyo, and Merck & Co., Inc.
- Accumetrics
- Schering-Plough/Merck & Co., Inc., Bayer HealthCare, Bristol-Myers Squibb, Sanofi-Aventis, AstraZeneca, Johnson and Johnson, Roche, GlaxoSmithKline, and Novartis
- AstraZeneca, Bayer HealthCare, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, GlaxoSmithKline, Menarini, Merck & Co., Inc., Pfizer Inc., and Sorin Medica
- Servier
- Eli Lilly and Company/Daiichi Sankyo, Merck & Co., Inc., Portola Pharmaceuticals, Sanofi-Aventis, Johnson & Johnson, Bristol-Myers Squibb, The Medicines Company, and AstraZeneca
- AstraZeneca, Merck & Co., Inc., Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer Inc., and GlaxoSmithKline
- AstraZeneca and Bristol-Myers Squibb/Pfizer Inc.
This publication has 14 references indexed in Scilit:
- A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trialHeart, 2013
- Third universal definition of myocardial infarctionEuropean Heart Journal, 2012
- Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trialEuropean Heart Journal, 2011
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2009
- Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialAmerican Heart Journal, 2009
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevationEuropean Heart Journal, 2008
- Universal Definition of Myocardial InfarctionCirculation, 2007
- ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineJournal of the American College of Cardiology, 2007
- Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trialAmerican Heart Journal, 2002
- Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT studyTrials, 2001